CN1615315A - 肿瘤特异性单克隆抗体 - Google Patents

肿瘤特异性单克隆抗体 Download PDF

Info

Publication number
CN1615315A
CN1615315A CNA028270959A CN02827095A CN1615315A CN 1615315 A CN1615315 A CN 1615315A CN A028270959 A CNA028270959 A CN A028270959A CN 02827095 A CN02827095 A CN 02827095A CN 1615315 A CN1615315 A CN 1615315A
Authority
CN
China
Prior art keywords
ser
gly
thr
ala
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028270959A
Other languages
English (en)
Chinese (zh)
Inventor
J·D·瓦特金斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Molecular Evolution Inc
Original Assignee
Applied Molecular Evolution Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Molecular Evolution Inc filed Critical Applied Molecular Evolution Inc
Publication of CN1615315A publication Critical patent/CN1615315A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA028270959A 2001-11-19 2002-11-19 肿瘤特异性单克隆抗体 Pending CN1615315A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98990101A 2001-11-19 2001-11-19
US09/989,901 2001-11-19

Publications (1)

Publication Number Publication Date
CN1615315A true CN1615315A (zh) 2005-05-11

Family

ID=25535569

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028270959A Pending CN1615315A (zh) 2001-11-19 2002-11-19 肿瘤特异性单克隆抗体

Country Status (8)

Country Link
EP (1) EP1446416A4 (pt)
JP (1) JP2005517388A (pt)
CN (1) CN1615315A (pt)
AU (1) AU2002365978A1 (pt)
BR (1) BR0214288A (pt)
CA (1) CA2467020A1 (pt)
MX (1) MXPA04004658A (pt)
WO (1) WO2003044036A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679516B (zh) * 2007-05-31 2013-11-13 默沙东公司 靶向金黄色葡萄球菌ORF0657n的抗原结合蛋白
BR112013029550A2 (pt) 2011-05-17 2022-04-19 California Inst Of Techn Anticorpos neutralizantes de vírus de imunodeficiência humana e métodos de uso dos mesmos
BR112020021271A2 (pt) 2018-04-17 2021-01-26 Celldex Therapeutics, Inc. construtos bispecíficos e anticorpos anti- cd27 e anti-pd-l1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281335B1 (en) * 1993-10-08 2001-08-28 Coulter Corporation Hybridoma and anti-KC-4 humanized monoclonal antibody
CA2229043C (en) * 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
KR20000015893A (ko) * 1996-05-22 2000-03-15 댄 마이클 특이적으로 암세포를 검출하는 항원 결합 단편, 상기 단편을 코딩하는 뉴클레오티드 및 암의 예방 및 검출에 사용되는 이들의 용도
US6303323B1 (en) * 1997-10-21 2001-10-16 Cancer Research Campaign Technology Limited Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies
US6787638B1 (en) * 1998-12-02 2004-09-07 Applied Molecular Evolution, Inc. Tumor specific human monoclonal antibodies and methods of use
IT1307864B1 (it) * 1999-04-20 2001-11-19 Istituto Naz Per La Ricerca Su Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di

Also Published As

Publication number Publication date
MXPA04004658A (es) 2004-08-13
AU2002365978A1 (en) 2003-06-10
EP1446416A1 (en) 2004-08-18
WO2003044036A1 (en) 2003-05-30
BR0214288A (pt) 2004-11-09
JP2005517388A (ja) 2005-06-16
CA2467020A1 (en) 2003-05-30
EP1446416A4 (en) 2005-11-30

Similar Documents

Publication Publication Date Title
CN1898264A (zh) 用新的抗il13单克隆抗体治疗癌症
CN1620468A (zh) 新的抗igf－ir抗体及其应用
CN1596313A (zh) 人源化的胶原抗体及相关方法
CN1946422A (zh) 针对血管内皮生长因子的人源化抗体
CN101074261A (zh) Trail受体1和/或trail受体2特异性抗体及其应用
CN1547590A (zh) 人源化抗-LT-β-R抗体
CN1252076A (zh) 抗人抗原受体的新的生产方法及其用途
CN101035809A (zh) 抗tag－72的人源化单克隆抗体
CN1889979A (zh) Ip－10抗体及其用途
CN1889978A (zh) 干扰素α抗体及其用途
CN1678633A (zh) 抗igf－i受体抗体
CN1809592A (zh) 识别n－乙醇酰gm3神经节苷脂的重组抗体和片段以及其在肿瘤诊断和治疗上的应用
CN1795009A (zh) 抗－cd33抗体和使用其治疗急性髓性白血病的方法
CN1922199A (zh) Ca6抗原特异性细胞毒性偶联物及其应用方法
CN1541224A (zh) 拮抗性抗-hTNFSF13b人抗体
CN1602317A (zh) 血管生成素－2的特异结合剂
CN1905897A (zh) 拮抗性抗－cd40单克隆抗体和它们的使用方法
CN1886426A (zh) 结合白细胞介素－4受体的抗体
CN1829806A (zh) 产生高亲和力抗体的方法
CN1878790A (zh) 可中和的hgf表位和与其结合的中和抗体
CN1950107A (zh) Irta－5抗体及其用途
CN1606453A (zh) Cripto阻断抗体及其用途
CN101058609A (zh) 人源抗体及其表达
CN1575303A (zh) 人cdr－移植抗体及其抗体片段
CN1929862A (zh) 拮抗性抗－cd40单克隆抗体治疗慢性淋巴细胞性白血病的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075254

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1075254

Country of ref document: HK